This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiovascular disease	Toll-like receptor 3 (TLR3)	<p>Studies in mice suggest that agonizing TLR3 could help treat cardiovascular diseases. In a mouse model of mechanical arterial injury, a TLR3 agonist decreased arterial thickening compared with vehicle control. Next steps include identifying agonists of the TLR3 pathway and studying their effects in chronic diseases.</p> <p>Idera Pharmaceuticals Inc. has a TLR3 agonist in preclinical testing to treat hepatitis.</p> <p>Innate Pharma S.A.'s IPH 3102, also a TLR3 agonist, is in preclinical testing to treat cancer.</p> <p>SciBX 4(5); doi:10.1038/scibx.2011.129 Published online Feb. 3, 2011</p>	Patent application filed; available for licensing	<p>Cole, J.E. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Jan. 10, 2011; doi:10.1073/pnas.1018515108</p> <p>Contact: Claudia Monaco, Imperial College London, London, U.K. e-mail: c.monaco@imperial.ac.uk</p> <p>Contact: Marc Feldmann, same affiliation as above e-mail: m.feldmann@imperial.ac.uk</p>